Summary
Ionis Pharmaceuticals, Inc. (Ionis) formerly ISIS Pharmaceuticals, Inc. is clinical stage biopharmaceutical company which focuses on the discovery and development of RNA-targeted drugs. The company focuses on developing first in-class medicines for the treatment of cardiovascular and metabolic disorders, cancer and rare diseases. The company develops its products based on its proprietary antisense technology. Its lead product candidates in Phase III development include Kynamro injection being developed in collaboration with Genzyme for the reduction of low-density lipoprotein cholesterol in patients suffering from homozygous familial hypercholesterolemia, or HoFH; Volanesorsen being developed for the treatment of rare, genetic disorders marked by severely high triglyceride levels; IONIS-TTRRx, a first-in-class drug for the treatment of all forms of TTR amyloidosis and Nusinersen being developed for the spinal muscular atrophy (SMA). The company operates through its wholly owned subsidiary, Akcea Therapeutics. Ionis is headquartered in Carlsbad, California, the US.
Ionis Pharmaceuticals, Inc. (IONS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Ionis Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 11
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
Biogazelle Enters into Research Agreement with Isis Pharma 14
Isis Pharma to Enter into Agreement with AstraZeneca 15
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 16
AstraZeneca Expands Co-Development Agreement with Isis Pharma 17
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 18
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 20
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 22
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 24
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 26
Isis Pharma Enters Into Collaboration With Xenon Pharma 28
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma 29
Licensing Agreements 30
Isis Pharma Enters into Licensing Agreement with Bayer HealthCare 30
Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 32
Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 33
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 35
Isis Pharma Enters Into Licensing Agreement With AstraZeneca 37
GlaxoSmithKline Amends Licensing Agreement With Isis Pharma For ISIS-TTRRx 39
Atlantic Healthcare Enters Into Licensing Agreement With Isis Pharma 41
GlaxoSmithKline Enters Into Licensing Agreement With Isis Pharma 42
Equity Offering 44
Isis Pharma Completes Public Offering Of Shares For US$182.7 Million 44
iCo Therapeutics Completes Private Placement Of US$0.91 Million Upon Exercise Of Warrants 46
Debt Offering 47
Isis Pharma Completes Private Placement of Notes for USD500 Million 47
Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For US$201 Million 49
Acquisition 51
Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma 51
Ionis Pharmaceuticals, Inc. - Key Competitors 53
Key Employees 54
Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
List of Tables
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Ionis Pharmaceuticals, Inc., Deals By Therapy Area, 2010 to YTD 2016 9
Ionis Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 11
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 12
Biogazelle Enters into Research Agreement with Isis Pharma 14
Isis Pharma to Enter into Agreement with AstraZeneca 15
Isis Pharma Enters into Agreement with Janssen Biotech to Discover and Develop RNA-Targeted Therapeutics 16
AstraZeneca Expands Co-Development Agreement with Isis Pharma 17
Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 18
Roche Enters Into Co-Development Agreement With Isis Pharma For Huntington's Disease Treatment 20
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 22
Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 24
Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 26
Isis Pharma Enters Into Collaboration With Xenon Pharma 28
iCo Therapeutics Enters Into Technology Transfer Agreement With Isis Pharma 29
Isis Pharma Enters into Licensing Agreement with Bayer HealthCare 30
Alnylam Pharma Enters into Licensing Agreement with Isis Pharma 32
Isis Pharma Enters into Licensing Agreement with Alnylam Pharma 33
Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 35
Isis Pharma Enters Into Licensing Agreement With AstraZeneca 37
GlaxoSmithKline Amends Licensing Agreement With Isis Pharma For ISIS-TTRRx 39
Atlantic Healthcare Enters Into Licensing Agreement With Isis Pharma 41
GlaxoSmithKline Enters Into Licensing Agreement With Isis Pharma 42
Isis Pharma Completes Public Offering Of Shares For US$182.7 Million 44
iCo Therapeutics Completes Private Placement Of US$0.91 Million Upon Exercise Of Warrants 46
Isis Pharma Completes Private Placement of Notes for USD500 Million 47
Isis Pharma Completes Private Placement Of Convertible Senior Notes Due 2019 For US$201 Million 49
Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma 51
Ionis Pharmaceuticals, Inc., Key Competitors 53
Ionis Pharmaceuticals, Inc., Key Employees 54
Ionis Pharmaceuticals, Inc., Subsidiaries 55
List of Figures
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Ionis Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Ionis Pharmaceuticals, Inc., Medical Devices Deals, 2010 to YTD 2016 11
